What type of study is this?

This is a Systematic Review study (also classified as: Meta-Analysis).

August 22, 2025BMC GastroenterologyOpen Access

Mycophenolate mofetil versus azathioprine as a first-line treatment for autoimmune hepatitis: a comparative systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

Systematic review finds mycophenolate mofetil enhances remission rates in autoimmune hepatitis, suggesting a safer alternative to azathioprine.

Mycophenolate mofetil offers higher complete biochemical remission rates compared to azathioprine in autoimmune hepatitis treatment.
Short-term complete biochemical remission rates improved significantly with mycophenolate mofetil, showing an odds ratio of 2.56.
The study performed a comprehensive systematic review involving four studies and over 500 patients to assess treatment efficacy.
Mycophenolate mofetil was associated with fewer serious adverse events, indicating a safer profile for first-line treatment of autoimmune hepatitis.

Ali et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Systematic review finds mycophenolate mofetil enhances remission rates in autoimmune hepatitis, suggesting a safer alternative to azathioprine.